https://www.selleckchem.com/pr....oducts/sar439859.htm
, anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy. (Funded by Novartis; REACH2 ClinicalTrials.gov number, NCT02913261.). Copyright © 2020 Massachusetts Medical Society.The paper describes the occurrence of a rare complication - portal and systemic venous air embolism - after en
Like
Comment
Share
